ELIEM THERAPEUTICS INC (ELYM) Stock Fundamental Analysis

NASDAQ:ELYM • US28658R1068

5.11 USD
-0.05 (-0.97%)
At close: Oct 2, 2024
5.1 USD
-0.01 (-0.2%)
After Hours: 10/2/2024, 8:06:17 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

ELYM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. ELYM has a great financial health rating, but its profitability evaluates not so good. ELYM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • ELYM had negative earnings in the past year.
  • ELYM had a positive operating cash flow in the past year.
  • In the past 5 years ELYM always reported negative net income.
  • ELYM had a negative operating cash flow in each of the past 5 years.
ELYM Yearly Net Income VS EBIT VS OCF VS FCFELYM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

  • With a decent Return On Assets value of -28.40%, ELYM is doing good in the industry, outperforming 70.77% of the companies in the same industry.
  • The Return On Equity of ELYM (-28.88%) is better than 80.11% of its industry peers.
Industry RankSector Rank
ROA -28.4%
ROE -28.88%
ROIC N/A
ROA(3y)-31.78%
ROA(5y)-44.63%
ROE(3y)-32.97%
ROE(5y)-48.21%
ROIC(3y)N/A
ROIC(5y)N/A
ELYM Yearly ROA, ROE, ROICELYM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ELYM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELYM Yearly Profit, Operating, Gross MarginsELYM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, ELYM has more shares outstanding
  • There is no outstanding debt for ELYM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ELYM Yearly Shares OutstandingELYM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
ELYM Yearly Total Debt VS Total AssetsELYM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 53.84 indicates that ELYM is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 53.84, ELYM belongs to the top of the industry, outperforming 98.06% of the companies in the same industry.
  • There is no outstanding debt for ELYM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 53.84
ROIC/WACCN/A
WACCN/A
ELYM Yearly LT Debt VS Equity VS FCFELYM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 60.41 indicates that ELYM has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 60.41, ELYM belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • ELYM has a Quick Ratio of 60.41. This indicates that ELYM is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 60.41, ELYM belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 60.41
Quick Ratio 60.41
ELYM Yearly Current Assets VS Current LiabilitesELYM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for ELYM have decreased strongly by -27.15% in the last year.
EPS 1Y (TTM)-27.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-851.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ELYM will show a very strong growth in Earnings Per Share. The EPS will grow by 23.41% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60%
EPS Next 2Y23.41%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELYM Yearly EPS VS EstimatesELYM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ELYM. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELYM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELYM Price Earnings VS Forward Price EarningsELYM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELYM Per share dataELYM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

  • ELYM's earnings are expected to grow with 23.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.41%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ELYM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ELIEM THERAPEUTICS INC

NASDAQ:ELYM (10/2/2024, 8:06:17 PM)

After market: 5.1 -0.01 (-0.2%)

5.11

-0.05 (-0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-04
Earnings (Next)N/A
Inst Owners84.1%
Inst Owner Change-29.32%
Ins Owners7.95%
Ins Owner Change0%
Market Cap342.68M
Revenue(TTM)N/A
Net Income(TTM)-64.19M
Analysts43.33
Price Target4.59 (-10.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF 6230.48
P/B 1.54
P/tB 1.54
EV/EBITDA N/A
EPS(TTM)-2.15
EYN/A
EPS(NY)-0.63
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)0
OCFY0.02%
SpS0
BVpS3.31
TBVpS3.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.4%
ROE -28.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.78%
ROA(5y)-44.63%
ROE(3y)-32.97%
ROE(5y)-48.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 60.41
Quick Ratio 60.41
Altman-Z 53.84
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-851.87%
EPS Next Y60%
EPS Next 2Y23.41%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-110.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y89.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y100.12%
OCF growth 3YN/A
OCF growth 5YN/A

ELIEM THERAPEUTICS INC / ELYM FAQ

What is the ChartMill fundamental rating of ELIEM THERAPEUTICS INC (ELYM) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ELYM.


What is the valuation status for ELYM stock?

ChartMill assigns a valuation rating of 1 / 10 to ELIEM THERAPEUTICS INC (ELYM). This can be considered as Overvalued.


How profitable is ELIEM THERAPEUTICS INC (ELYM) stock?

ELIEM THERAPEUTICS INC (ELYM) has a profitability rating of 2 / 10.


Can you provide the financial health for ELYM stock?

The financial health rating of ELIEM THERAPEUTICS INC (ELYM) is 8 / 10.


What is the earnings growth outlook for ELIEM THERAPEUTICS INC?

The Earnings per Share (EPS) of ELIEM THERAPEUTICS INC (ELYM) is expected to grow by 60% in the next year.